Gonzaga University and U.S. Bank Expand Partnership With a New Debit Card Design
SPOKANE, Wash.--(BUSINESS WIRE)--Gonzaga University supporters can now show their school pride with the new U.S. Bank Visa® Debit Card with the Gonzaga University design from U.S. Bank. The card was launched on May 11, 2025, and features College Hall, the campus' oldest building.
Opened in 2006, the U.S. Bank branch and ATM is located inside Gonzaga's John J. Hemmingson Center at 702 E Desmet Ave. Generously supporting the Gonzaga community, U.S. Bank provides $75,000 each year to Gonzaga's general scholarship fund.
'We're proud of our longstanding partnership with U.S. Bank, which has made a meaningful impact on Gonzaga students for two decades,' said Kara Hertz, assistant vice president of alumni and external relations. 'The new debit card design featuring our iconic College Hall is a great way for our community to show their Zag pride while supporting future scholarships.'
'We are very excited to expand the bank's connection with Gonzaga University and provide students, faculty, staff and supporters the opportunity to showcase their school spirit,' said Brian Young, U.S. Bank district manager for Eastern Washington. 'It's important for U.S. Bank to continue offering our knowledge, services and tools to the GU community. Featuring College Hall, a storied representation of higher education in Spokane, this debit card design signifies our commitment to the GU family.'
Gonzaga students were included in the debit card design process by voting on their favorite among three card designs. Each student who voted received a $5 Starbucks gift card for their participation. More than 800 students cast a vote, ultimately leading to the winning design of the close-up view of College Hall and the St. Ignatius of Loyola Statue.
This is the first U.S. Bank debit card design with Gonzaga University. The U.S. Bank Debit Card with the Gonzaga University design is the tenth school featured in the program, which started in 2020. So far, more than 100,000 customers have chosen to show their school pride right on their debit card.
The new cards can be ordered through usbank.com, by using the award-winning U.S. Bank Mobile App, or when visiting a local branch. From industry-leading video banking options to friendly, reliable in-person service, U.S. Bank is building the bank of the future by combining digital technology with a human presence.
About U.S. Bancorp
U.S. Bancorp, with approximately 70,000 employees and $676 billion in assets as of March 31, 2025, is the parent company of U.S. Bank National Association. Headquartered in Minneapolis, the company serves millions of customers locally, nationally and globally through a diversified mix of businesses including consumer banking, business banking, commercial banking, institutional banking, payments and wealth management. U.S. Bancorp has been recognized for its approach to digital innovation, community partnerships and customer service, including being named one of the 2025 World's Most Ethical Companies and one of Fortune's most admired superregional banks. Learn more at usbank.com/about.
Deposit products are offered by U.S. Bank National Association. Member FDIC.
The U.S. Bank Visa® Debit Card is issued by U.S. Bank National Association, pursuant to a license from Visa U.S.A. Inc.
About Gonzaga University
Gonzaga University, established in Spokane, Wash. in 1887, is a nationally ranked liberal arts institution that educates students for lives of leadership and service for the common good. In keeping with its Catholic, Jesuit, and humanistic heritage and identity, Gonzaga models and expects excellence in academic and professional pursuits and intentionally develops the whole person – intellectually, spiritually, culturally, physically and emotionally. Gonzaga offers 16 undergraduate degrees through 53 majors, 68 minors and 73 concentrations; 23 master's programs; and five doctorate degrees, through the College of Arts and Sciences and six schools: School of Business Administration, School of Education, School of Engineering and Applied Science, School of Health Sciences, School of Leadership Studies, and School of Law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Yahoo
an hour ago
- Yahoo
VSI Leads Groundbreaking National Study Showing Holistic Recovery Program Improves Spine Surgery Outcomes
Study of 50,000+ patients shows Enhanced Surgical Recovery protocol leads to faster healing, reduced opioid use, and fewer re-admissions after spinal fusion surgery RESTON, Va., June 5, 2025 /PRNewswire/ -- Spine surgeons at VSI® have led one of the largest nationwide studies of its kind, revealing that a more comprehensive, patient-centered approach to spine surgery recovery can lead to faster healing, reduced pain, and fewer complications. The research, which analyzed outcomes from more than 50,000 thoracolumbar spinal fusion cases by 1,352 surgeons at 138 centers across the US, validates the effectiveness of an Enhanced Surgical Recovery (ESR) program developed and implemented by VSI's expert team. This research was conducted in collaboration with the HCA Healthcare Spine Research Consortium. "Spine surgery has come a long way, but recovery is where the real transformation happens," explains lead author Dr. Christopher Good, MD, a spine surgeon and the president and CEO of VSI. "With Enhanced Surgical Recovery, we're not just performing successful surgeries; we're empowering patients to heal faster, use less medication, and return to their lives with fewer setbacks. This research proves that when we treat the whole patient, we achieve dramatically better outcomes." A New Standard in Spine Surgery RecoveryThe evidence-based Enhanced Surgical Recovery (ESR) program is a multiphase protocol designed to optimize patient outcomes before, during, and after spinal fusion surgery. It includes pre-surgical education, opioid-sparing anesthesia techniques, and early initiation of mobility and nutrition to accelerate healing and reduce dependence on medications. "This movement is about reimagining what it means to recover from spine surgery," spine surgeon and co-author Dr. Ehsan Jazini says. "We're proving that with the right preparation and post-op care, patients can recover faster, get back to life, and avoid unnecessary complications." Key Findings from the Research Study: Less Pain Medication: Patients in the ESR program used an average of 8 fewer morphine-equivalent milligrams per day. Shorter Hospital Stays: The average patient stay was reduced by nearly half a day (86 hours vs. 98 hours). Fewer Re-admissions: ESR patients had a significantly lower 30-day re-admission rate (5.8% vs. 6.7%), and for single-level surgeries, re-admissions dropped from 5.6% to just 4.2%. About Thoracolumbar Spinal Fusion Surgery:Thoracolumbar spinal fusion is used to stabilize the spine by permanently joining two or more vertebrae in the mid-to-lower back. It is commonly used to treat: Degenerative disc disease Scoliosis Spinal fractures Spondylolisthesis Spinal stenosis Tumors or infections of the spine This surgical procedure can significantly reduce pain, correct spinal deformities, and prevent further deterioration, but recovery is key to long-term success. About VSI:VSI (formerly Virginia Spine Institute), based in Reston, VA, is a nationally recognized leader in spinal healthcare, offering advanced surgical and non-surgical solutions tailored to each patient. With over 30 years of experience and more than 100,000 patients treated, VSI delivers proven outcomes through its personalized, concierge-style approach. For more resources and spine support, listen to the Get Back To Your Life® podcast on iTunes, Spotify, and YouTube. View original content to download multimedia: SOURCE VSI
Yahoo
2 hours ago
- Yahoo
Creative Tech Textile's Seawool® Opens New Horizons for Sustainable Fashion
For World Environment Day, the company is sharing how material innovation can help the global fashion industry meet its sustainability goals. TAINAN, June 5, 2025 /CNW/ -- In celebration of World Environment Day, Creative Tech Textile is sharing the success story behind Seawool® — its innovative material transforming discarded oyster shells and recycled plastic into a sustainable textile solution. This pioneering approach shows how reusing natural waste can move fashion toward a more sustainable future. Fashion's Push to Become More Sustainable The global fashion industry has recently faced growing pressure to become more sustainable. According to the World Economic Forum, incorporating recycled materials into clothing could reduce CO₂ emissions by up to 80%. Yet, polyester—plastic-based and derived from fossil fuels—remains the most widely used fiber in textiles, while less than 1% of clothing materials are recycled into new garments, per the Geneva Environment Network. In particular, there is a growing need to reduce short-lifecycle plastic-based fabrics and increase uptake of circular, low-impact material innovations. Seawool®: The 'Emerald from the Ocean' Creative Tech's proprietary Seawool® material represents a bold leap in sustainable material development. By blending discarded oyster shells from Taiwan with recycled PET plastic bottles, the company has created a textile that is as functional as it is environmentally conscious. Already adopted by leading US apparel brands, Seawool® generates around TWD$200 million (US$6.1 million) in annual revenue and is quickly gaining global traction. In May, Creative Tech showcased Seawool® at PanTextiles Tokyo, an international trade event by the Taiwan Textile Federation. "As consumers grow more conscious of their clothing's environmental impact, we want them to know sustainable material innovations like Seawool® exist and are scalable," noted Eddie Wang, Founder and CEO of Creative Tech Textile. "Our goal is to replace traditional fibers with more environmentally-friendly alternatives — facilitating true sustainability from the upstream end of the fashion industry supply chain." Creative Tech currently produces 2,500 tons of Seawool® annually, repurposing approximately 500 tons of oyster shells. How Seawool® Compares to Traditional Materials Seawool® stands out for both its environmental footprint and fabric properties: Odor-resistant Moisture-wicking Offers UV protection Furthermore, the oyster shell powder inside is a low thermal conductivity material, offering temperature stability. Seawool® also has cost and environmental advantages: 1/10 the cost of down 1/20 the cost of high-grade wool Lower water usage compared to down and wool Performs better for water absorption than polyester Improved odor resistance compared with cotton Comparable thermal regulation to pricier low-conductivity fabrics, but at 1/6 to 1/10 the cost A sustainable world inside an oyster shell While Taiwan produces an estimated 100,000 tons of oyster shells annually, far greater quantities are generated in the US and China, highlighting the abundance of this natural raw material. Turning oyster shells into functional powder requires a specialized process which Creative Tech has mastered with unique production advantages that support large-scale manufacturing. As demand for eco-conscious materials grows, Creative Tech is well-placed to deliver consistent quality and scale for fashion brands seeking sustainable alternatives. About Creative Tech Textile Founded in 2010 and based in Tainan, Taiwan, Creative Tech Textile is a leading innovator in sustainable textiles. Best known for its proprietary, patented Seawool® material—made from discarded oyster shells and recycled PET bottles—the company delivers high-performance fabrics with natural softness, thermal regulation, and odor resistance. As a Bluesign®-certified manufacturer, Creative Tech helps global apparel brands adopt circular, eco-friendly textiles. For more information, visit: View original content to download multimedia: SOURCE Creative Tech Textile View original content to download multimedia:
